Tepanil Ten-Tab, 75 mg, Controlled Release Tablets (Diethylpropion hydrochloride)
Diethylpropion hydrochloride, a sympathomimetic agent.
Diethylpropion hydrochloride tablets are indicated in the management of exogenous obesity as a short-term adjunct (a few weeks) in a regiment of weight reduction based on caloric restriction. The usefulness of agents of this class should be measured against possible risk factors inherent in their use such as those described (see CLINICAL PHARMACOLOGY).
Published Studies Related to Tepanil (Diethylpropion)
A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects. [2009.08]
OBJECTIVE: To evaluate the efficacy of diethylpropion on a long-term basis, with emphasis in cardiovascular and psychiatric safety aspects... CONCLUSION: Diethylpropion plus diet produced sustained and clinically significant weight loss over 1 year. It seems to be safe in relation to cardiovascular and psychiatric aspects in a well-selected population.
Clinical Trials Related to Tepanil (Diethylpropion)
Diphenoxylate / Atropine to Decrease FDG Activity During F-18 FDG PET [Completed]
2-[18F]-fluoro-2-deoxyD-glucose positron emission tomography (FDG PET) has proven to be a
valuable clinical tool for the staging and surveillance of lymphoma. 1-6 Occasionally, lymph
nodes in the mesentery and retroperitoneum can be difficult to distinguish from normal bowel
activity on PET scans despite three-plane and cine maximal image projection (MIP) imaging.
This uncertainty limits the clinical usefulness of PET in some cases of lymphoma. 7-8 In
addition, bowel activity can also hinder interpretation of PET scans in other types of solid
tumors including melanoma and colorectal cancer. 6,9,10 Our goal is to determine how well
diphenoxylate/atropine 5mg/0. 05mg (Lomotil) decreases bowel activity and how this decrease
impacts clinical decision-making, specifically for lymphoma staging and surveillance. This is
a prospective, randomized, double-blinded study involving 60 patients undergoing PET scans
for newly diagnosed or recurrent, untreated lymphoma.
LOSS- Louisiana Obese Subjects Study [Active, not recruiting]
LOSS is a pragmatic clinical evaluation of intensive medical approaches to weight loss for
individuals with extreme obesity (body mass index [BMI] 40-60 kg/m2). The intensive medical
treatment is designed to produce 25% weight loss from baseline and to maintain at least 20%
weight loss from baseline. The intensive medical treatment is compared to a usual care
treatment model where individuals utilize self directed approaches to weight loss. The
active treatment period is three years, followed by two years of observation.
Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse [Completed]
This research is being done to evaluate if NRP104 is a safe drug. The other purpose is to
learn if NRP104 produces a high and any other effects like amphetamine and other stimulant
drugs that are abused. This information will give some indication if NRP104 can be abused.
NRP104 is an investigational drug. This means that it has not been approved by the U. S. Food
and Drug Administration (FDA). Healthy people, between the ages of 18 and 55 with histories
of substance abuse that include stimulant drugs, may join. Amphetamines are drugs that are
used most often to treat attention deficit hyperactivity disorder (ADHD) in children, to
treat narcolepsy (excessive sleepiness) and for weight loss.
Page last updated: 2009-10-20